The Platform Trial Takeover: Neurology’s Last Best Chance to Stop Failing Patients
Multi-arm multi-stage platform trials could cut neurodegenerative drug timelines in half—but FDA adaptive design rules haven't caught up with...
The Oversight Gap Nobody Is Naming: State Sandboxes Are Filling a Void the FDA Has Left Open
Utah's clinical AI sandbox and the FDA's 1,451 AI device authorizations reveal a structural oversight gap—states are building what...
When Phase 2b Wins and Phase 3 Fails: The Biomarker Stratification Crisis Hidden Inside Astegolimab’s COPD Data
Genentech's astegolimab cut COPD exacerbations in ALIENTO but missed significance in Phase 3 ARNASA—exposing a broken biomarker stratification logic...
The TOBRA Trial Just Killed a Widely Used Surgical Assumption — And Most Orthopedic Programs Haven’t Noticed Yet
A 1,660-patient RCT across 39 U.S. trauma centers found tobramycin adds nothing over vancomycin alone for preventing deep SSIs...
DIPG’s Biomarker Reckoning: What BIOMEDE Tells Us About Precision Oncology Trial Design When the Primary Endpoint Fails
BIOMEDE screened 279 DIPG patients across 45 centers using biopsy-driven tumor profiling — and its biomarker signals outlasted its...
The Survival Signal That Should Redesign Every RAS-Mutant Pancreatic Trial Running Right Now
Daraxonrasib cut pancreatic cancer mortality nearly in half vs. chemo in the RASolute 302 Phase 3 trial — here's...
Five Approvals, Nine Expansions: What the EMA’s April CHMP Meeting Reveals About Where Global Drug Development Is Heading
EMA's CHMP recommended 5 new medicines and 9 indication expansions in its April 20–23 meeting — here's what the...
Loper Bright Is Rewriting FDA’s Authority Over Synthetic Biology — Before the Industry Knows It
The Supreme Court's Loper Bright ruling is quietly dismantling FDA's deference-based regulatory hold over synthetic biology, and clinical programs...
The Basket Trial Is the New Black — and the FDA Hasn’t Caught Up
Arrowhead Pharmaceuticals' Phase 1 basket trial of zodasiran enrolled five distinct lipid disorder populations under a single protocol —...
The GLP-1 Pill Just Broke Every Obesity Trial Playbook
The FDA's approval of oral orforglipron for obesity isn't just a formulation win — it's a structural disruption to...